Navigation Links
NW Bio Issues Statement on Highly Unusual Trading Activity
Date:10/19/2015

BETHESDA, Md., Oct. 19, 2015 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the recent highly unusual trading activity in the Company's stock:

NW Bio is not aware of any fundamental reason for the substantial decline in the price of the Company's stock on Friday, October 16.  Indeed, NW Bio presented encouraging clinical data at scientific conferences in London and New York as recently as mid-September. 

The Company's clinical data update included promising ongoing interim survival data from both the Phase I trial of DCVax-Direct in 13 diverse cancers, and the Information Arm of 51 patients who were unable to enroll in the Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer because of apparent early tumor recurrence.  

In the DCVax-Direct trial for patients with multiple inoperable metastatic tumors who had failed standard treatments (including multiple different chemotherapy regimens), half of these patients are still alive with survival times now ranging up to 22 months, exceeding expected survival times.

In the DCVax-L Information Arm, for the 25 GBM patients with apparent early tumor recurrence at one of two time points, 40% of the patients have now reached or exceeded approximately 3 years' survival.  This substantially exceeds the expected survival time of about 15 months even for regular GBM patients without early tumor recurrence.

NW Bio noted that the Company's shares have experienced highly unusual trading activity since the September release of positive data, including especially on Friday, October 16, when more than 2.9 million NW Bio shares were traded, representing five times its recent average daily trading volume.  The Company believes this activity is part of an ongoing effort to drive its stock price lower through an orchestrated campaign, including questionable short selling activity.  The Company is intensifying its investigation and gathering of evidence.   

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which is on a partial clinical hold in regard to new screening of patients. GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors cancers.  It has completed enrollment in the Phase I portion of the trial.  The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing and expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - http://photos.prnewswire.com/prnh/20110329/SF73084LOGO

 


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Noninvasive Imaging Method Looks Deeper Inside the Body to Study Living Brain and Other Tissues
2. Kairos Society Reveals 2015’s Kairos 50 Young Entrepreneurs Tackling World Issues, Announces Kairos Global Summit in Hollywood October 13
3. Portage Issues Letter to Shareholders
4. Depomed Issues Statement on Horizon Pharma plcs Unsolicited Exchange Offer
5. Collaborative Issues Initial Guidelines for Health Insurance Coverage of Next Generation Sequencing (NGS) Testing in Oncology
6. WebMD and Medscape Surveys Explore Health Issues Facing Children, Parents and Physicians in Upcoming School Year
7. MabVax Therapeutics Issues Letter to Stockholders
8. U.S. PTO Issues Notice of Allowance for Patent using TB4 for Improving Neurological Outcomes After Injury and Neurodegenerative Disease
9. Spherix Issues A Litigation Update
10. OncoSec Medical Issues Annual Letter To Shareholders
11. Marianjoy Scholarship Program Issues 24 Scholarships to Students with Physical Disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2019)... ... August 29, 2019 , ... Prof. Stephen R. Byrn ... in Africa program, which includes a master’s degree in biotechnology innovation and regulatory ... through 13th, 2019. Topics to be addressed include Manufacturing, Quality, Regulation, Devices, ...
(Date:8/25/2019)... ... August 23, 2019 , ... Authors Gopal Nayak ... the scientific research book “Impact of Biofield Treatment on Growth and Anatomical Characteristics ... Patchouli. , The book garnered No. 1 status on Amazon in several ...
(Date:8/15/2019)... ... , ... PathSensors announced today that Roger Lawrence has joined ... of Food Technologists (IFT) Board of Directors, Illinois Institute of Technology (IIT) Institute ... and Applied Nutrition (JIFSAN) Advisory Council and the University of Maryland College of ...
(Date:8/8/2019)... , ... August 08, 2019 , ... ... Agents for sales and service organizations, today announced that the company’s Studio ... Award for the IVA market . Inference will officially accept the award at ...
Breaking Biology Technology:
(Date:8/27/2019)... JUPITER, Fla. (PRWEB) , ... August 27, 2019 ... ... developments in life science and drug development. This episode is scheduled to broadcast ... will explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show ...
(Date:8/23/2019)... (PRWEB) , ... August 22, 2019 , ... ... rebranding to Planet121 following their acquisition in June of 2018. Along with the ... and communications. , “Our goal was to create a cohesive brand that ...
(Date:8/21/2019)... ... August 20, 2019 , ... ... the second time since BioInformatics first fielded the survey in 2016. The ... Customer Experience , from BioInformatics, part of Science and Medicine Group. More than ...
Breaking Biology News(10 mins):